title: Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population.
abstract: Introduction. Anti-tumor necrosis factor (TNF) agents are effective for several immunologic conditions (rheumatoid arthritis (RA), Crohn's disease (CD), and psoriasis). The purpose of this study was to evaluate the efficacy and safety of anti-TNF agents via chart review. Methods. Single-site, retrospective cohort study that evaluated the efficacy and safety of anti-TNF agents in veterans initiated between 2010 and 2011. Primary aim evaluated response at 12 months post-index date. Secondary aims evaluated initial response prior to 12 months post-index date and infection events. Results. A majority of patients were prescribed anti-TNF agents for CD (27%) and RA (24%). Patients were initiated on etanercept (41%), adalimumab (40%), and infliximab (18%) between 2010 and 2011. No differences in patient demographics were reported. Response rates were high overall. Sixty-five percent of etanercept patients, 82% of adalimumab patients, and 59% of infliximab patients were either partial or full responders, respectively. Approximately 16%, 11%, and 12% of etanercept, adalimumab, and infliximab were non-responders, respectively. Infections between the groups were non-significant. Etanercept and adalimumab patients had higher but non-significant odds of being a responder relative to infliximab. Conclusions. Most patients initiated with anti-TNF agent were responders at 12 months follow-up for all indications in a veteran population.
authors.affiliation: Veterans Affairs San Diego Healthcare System , San Diego, CA , USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Bounthavong
authors.affiliation: Veterans Affairs San Diego Healthcare System , San Diego, CA , USA.
authors.forename: Nermeen
authors.initials: N
authors.lastname: Madkour
authors.affiliation: Veterans Affairs San Diego Healthcare System , San Diego, CA , USA.
authors.forename: Rashid
authors.initials: R
authors.lastname: Kazerooni
keywords: Adalimumab; Certolizumab; Cohort study; Crohn’s disease; Etanercept; Formulary management; Infliximab; Rheumatoid arthritis; Tumor necrosis factor; Veterans